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Abstract: Type 2 diabetes mellitus is an increasingly prevalent condition worldwide. The 
complications of this disease are known to signiﬁ  cantly increase the morbidity and mortality 
of those affected, resulting in substantial direct and indirect costs. Although good glycemic 
control has been shown to reduce the incidence and progression of diabetes-related microvas-
cular complications, blood glucose levels are not adequately controlled in most individuals 
with diabetes. The reasons for this are many, and include issues such as poor adherence to 
complex medication regimes; costs of prescribed therapies; and the failure of traditionally 
prescribed medications to preserve beta cell function over time. However, our armamentarium 
of glucose-lowering drugs has expanded recently with the development of medications that act 
via the incretin pathway. Sitagliptin, the ﬁ  rst commercially available dipeptidyl peptidase-4 
inhibitor, inhibits the metabolism and inactivation of the incretin hormones GLP-1 and GIP. The 
subsequent elevation in levels of these hormones and associated prolongation of their actions 
has been shown to increase insulin secretion and suppress glucagon secretion in a glucose-
appropriate fashion. Sitagliptin therapy in individuals with type 2 diabetes has been found to 
lower signiﬁ  cantly hemoglobin A1c (Hb1c) levels with a minimum of adverse side effects such 
as weight gain or hypoglycemia. Use of sitagliptin in conjunction with the insulin-sensitizing 
medication metformin has been shown to decrease HbA1c levels more signiﬁ  cantly than does 
either drug alone. This combination of medications is generally well tolerated, with no adverse 
effects on weight and a very low likelihood of treatment-related hypoglycemia. Use of both 
drugs will positively affect many of the underlying metabolic abnormalities associated with 
type 2 diabetes, including the disordered secretion of insulin and glucagon as well as impaired 
sensitivity to insulin which are known to accompany this disease. Animal studies also suggest 
that dipeptidyl peptidase-4 inhibitor treatment may help to preserve beta cell mass; however, it 
is unclear at present whether or not this will prove to be the case in humans.
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Introduction
Background and signiﬁ  cance
Diabetes mellitus is an increasingly prevalent condition worldwide. An estimated 20.8 
million individuals in the US have diabetes, with the number of newly diagnosed adults 
nearly tripling between 1980 and 2005 (CDC 2008). The World Health Organization 
estimates that approximately 180 million individuals are affected worldwide, with 
this number expected to double by the year 2030 (WHO 2008). It is well understood 
that the ﬁ  nancial and societal costs attributable to diabetes and its complications 
are substantial. In the US alone, estimated total costs associated with diabetes were 
estimated to be US$132 billion in the year 2002 (CDC 2008). Diabetes-related micro-
vascular complications are responsible for the majority of new cases of blindness, 
kidney failure, and nontraumatic amputations among US adults. Rates of stroke and 
heart-disease related deaths are 2–4 times higher in adults with diabetes than in the 
general population (CDC 2008).Vascular Health and Risk Management 2008:4(4) 744
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On a more positive note, intensive glycemic control will 
clearly slow the development and progression of many of 
these sequelae. This was convincingly demonstrated in the 
UK Prospective Diabetes Study (UKPDS), in which every 
1% drop in hemoglobin A1c (HbA1c) resulted in a 37% 
reduction in microvascular complications and a 21% reduc-
tion in any diabetes-related endpoint (Stratton et al 2000). 
As there was no threshold at which risk was not further 
reduced, it was hypothesized that a goal of normoglycemia 
might provide the best protection from these complica-
tions. As a result, increasingly strict recommendations for 
glycemic control have been issued by organizations such 
as the International Diabetes Federation (IDF) and the 
American Diabetes Association (ADA) (IDF 2008, ADA 
2008). Despite this, most individuals with diabetes do not 
achieve optimal glycemic control. The National Health 
and Nutrition Examination Survey (NHANES) 1999–2000 
found that only 37% of surveyed adults with diabetes had 
HbA1c values at the recommended ADA goal of 7%. 
Furthermore, only 7.3% of those individuals had achieved 
desirable control of the combined risk factors of glycemia, 
cholesterol, and hypertension (Saydah et al 2004). Although 
a variety of new glucose-lowering agents had become avail-
able in the interim, these percentages were unimproved 
compared with a similar survey performed in 1988–1994 
(Saydah et al 2004).
It is clear that there are numerous barriers to the achieve-
ment of adequate glycemic control. Although always a 
cornerstone of appropriate diabetes management, lifestyle 
modiﬁ  cation is unlikely to achieve either adequate or lasting 
control of hyperglycemia (Nathan et al 2006). Patient adher-
ence to complex treatment regimes may be poor, and in fact 
appears to be inversely related to the number of medication 
doses that must be taken daily (Barnett 2004). Health care 
providers may also have a limited understanding of the 
degree of glycemic lowering likely to be accomplished by 
the addition of any particular class of medication, and often 
delay intensiﬁ  cation of therapy until long after glycemic 
control has deteriorated. Most signiﬁ  cant, however, may 
be the inability of traditionally utilized glucose-lowering 
therapies to sustain adequate glycemic control over time. 
In the previously noted UKPDS trial, treatment with diet, 
sulfonylurea, or metformin monotherapy adequately con-
trolled diabetes for just half of the participants at 3 years, 
and only 25% of the participants at 9 years (Turner et al 
1999). In the more recent ADOPT trial (A Diabetes Out-
come Progression Trial), initial therapy with rosiglitazone 
resulted in greater durability of glycemic control than did 
treatment with metformin or glyburide (Kahn et al 2006). 
However, the signiﬁ  cant expense of rosiglitazone coupled 
with concerns regarding the drug’s cardiovascular safety 
have tempered the enthusiasm for its widespread use (Nissen 
and Wolski 2007).
Normal glucose homeostasis
The pancreatic islets are composed primarily of the beta 
cells, which produce insulin, and glucagon-producing alpha 
cells. In general, insulin is the hormone responsible for 
glucose disposal, glucagon for glucose availability. Under 
normal conditions these hormones work in concert to main-
tain glucose levels within a fairly narrow normal range. For 
example, food intake will promote insulin release, which 
will in turn increase formation of glycogen stores, facilitate 
glucose uptake in muscle and adipose tissues, and suppress 
hepatic glucose output, in part via paracrine suppression 
of glucagon release. The reduced glucagon secretion will 
limit hepatic glucose output through suppression of glycoge-
nolysis and gluconeogenesis. The opposite series of events 
will occur during the fasting state, in which the effects of 
glucagon predominate and insulin secretion is minimal 
(Aronoff et al 2004).
Pathophysiology of type 2 diabetes
In type 2 diabetes, multiple perturbations of these regula-
tory processes are known. The disease is characterized 
by both insulin resistance and at least a relative degree of 
insulin deﬁ  ciency. Factors such as aging, genetic predispo-
sition, obesity, and lack of physical activity are all thought 
to contribute to the development of insulin resistance in 
peripheral and hepatic tissues. Although the beta cells of the 
pancreas initially compensate by increasing insulin secretion, 
individuals destined to develop diabetes will not be able to 
sustain insulin production at a level adequate to maintain 
normoglycemia. Interestingly, though, not all individuals 
with insulin resistance will develop frank diabetes. Some 
authors, in fact, suggest that beta cell dysfunction – rather 
than insulin resistance – is the primary metabolic defect in 
type 2 diabetes (Gerich 2002). This hypothesis is supported 
by studies in ﬁ  rst-degree relatives of individuals with dia-
betes in which deﬁ  ciencies in beta cell function have been 
demonstrated prior to the onset of hyperglycemia (Gerich 
2002; Kahn 2003). Diabetes is also associated with a loss of 
normal oscillatory insulin release in response to meals; in 
particular, studies have demonstrated that the ﬁ  rst phase of 
insulin secretion (which serves to “prime” insulin-sensitive 
tissues to the inﬂ  ux of glucose associated with meals) is often Vascular Health and Risk Management 2008:4(4) 745
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absent in individuals with diabetes (Kahn 2003; Del Prato 
and Marchetti 2004). Inadequate suppression of glucagon 
secretion is known to contribute further to the resultant 
hyperglycemia (Aronoff et al 2004).
Although insulin resistance is a hallmark of type 2 
diabetes, the contribution of beta cell dysfunction to hyper-
glycemia cannot be underestimated. Data from studies such 
as the UKPDS suggest that beta cell function is generally 
diminished by more than 50% by the time an individual is 
diagnosed with diabetes (UKPDS 1995). In the UKPDS trial, 
progressive beta cell dysfunction was also noted in the years 
subsequent to diagnosis despite intervention with lifestyle 
modiﬁ  cation and/or treatment with oral glucose-lowering 
medication. This deterioration in beta cell function likely 
contributes signiﬁ  cantly to the difﬁ  culty in maintaining 
adequate glycemic control over time.
Role of the incretin hormones
Our understanding of islet physiology has increased sub-
stantially with the discovery of the gut-derived incretin 
hormones. The so-named “incretin effect” has been demon-
strated for years, and refers to the fact that an oral glucose 
load will stimulate insulin production to a greater degree 
than will glucose administered intravenously. Importantly, 
it is understood that the incretin effect is diminished in 
individuals with type 2 diabetes (Nauck et al 1986). The 
enhanced insulin secretion achieved through oral glucose 
loading is now understood to be due to the food-stimulated 
release of gut-derived hormones. The most important of 
these hormones are glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic peptide (GIP) (Aronoff 
et al 2004). GLP-1 (secreted by L cells of the small intestine) 
has a variety of effects on glucose homeostasis, including 
regulation of gastric emptying; the stimulation of insulin 
secretion in a glucose-dependent fashion; and the suppression 
of glucagon secretion (Drucker 2003). Both GLP-1 and GIP 
are rapidly degraded to largely inactive metabolites by the 
enzyme dipeptidyl peptidase-4 (DPP-4) (Drucker 2003). Indi-
viduals with type 2 diabetes are GLP-1 deﬁ  cient; however, 
infusion of GLP-1 to persons with diabetes has been shown 
to lower both postprandial and fasting blood glucose levels 
(Drucker 2003; Aronoff et al 2004). Nauck et al (1993) have 
demonstrated that GLP-1 administration to individuals with 
type 2 diabetes will facilitate glucose lowering via glucose-
dependent stimulation of insulin secretion and suppression 
of glucagon levels. Secreted by K cells of the small intestine, 
GIP is also known to stimulate insulin secretion; individuals 
with type 2 diabetes appear to have a diminished response 
to this hormone, rather than being deﬁ  cient in its production 
(Holst 2002; Drucker 2003).
Challenges and strategies in diabetes 
management
The optimal approach to glycemic management in type 
2 diabetes remains unclear, as the most commonly pre-
scribed diabetes therapies have proven largely ineffective 
in maintaining glucose control long term. A set of recently 
published guidelines are more aggressive than most, in that 
medical therapy with metformin is recommended (along 
with lifestyle modiﬁ  cation) at the time of diabetes diagno-
sis (Nathan et al 2008). However, based upon the UKPDS 
experience, it seems unlikely that this strategy alone will 
alter the known progression of beta cell dysfunction in type 
2 diabetes. Ideally, new therapies for diabetes management 
will effectively and adequately lower blood glucose, and 
increase the durability of that control once achieved. Our 
ever-expanding armamentarium of medications may make 
these goals more easily manageable. Effective glycemic 
control will likely require the use of medications that target 
both beta cell dysfunction and insulin resistance; furthermore, 
in order to maintain glycemic control over the long term, 
interventions that preserve beta cell function should probably 
be initiated early in the disease process. Although the most 
commonly prescribed diabetes medications are generally 
those in the insulin secretagogue and insulin-sensitizing 
categories, newer agents that utilize the incretin pathway 
offer exciting alternatives and may signiﬁ  cantly alter future 
diabetes management.
A variety of antihyperglycemic agents with differing and 
complementary mechanisms of action are currently avail-
able. Thoughtful combinations of these medications allow 
the prescriber to target many of the physiologic abnormali-
ties which are intrinsic to type 2 diabetes. Many studies to 
date suggest that combinations of different classes of oral 
antidiabetic drugs are more effective than are maximal 
doses of a single drug; in fact, many authors now suggest 
the use of combination therapy early – if not initially – in 
the disease process (DeFronzo 1999; Inzucchi 2002; Char-
pentier 2002; Riddle 2005). Combination therapy, in addi-
tion to being more effective than monotherapy, will often 
permit the utilization of submaximal doses of the agents 
used. Therefore, patients will derive the beneﬁ  ts of all drugs 
used, while minimizing the likelihood of intolerable side 
effects from any one class (Bell 2004). Several combina-
tion tablets are now available which help to defray the cost 
of diabetes management, and may improve adherence to Vascular Health and Risk Management 2008:4(4) 746
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prescribed therapy. In the remainder of this article, informa-
tion regarding the mechanism of action, safety, and efﬁ  cacy 
of the DPP-4 inhibitor sitagliptin will be reviewed, with a 
particular emphasis on its use in combination therapy with 
metformin. Studies thus far indicate that combinations of 
these two drugs are effective in blood glucose lowering, and 
may offer a more desirable side effect proﬁ  le than that seen 
with other classes of antihyperglycemic agents.
Mechanisms of glycemic control
Sitagliptin
Sitagliptin is one of several orally administered agents 
recently developed or in development which have been 
shown to inhibit the activity of the DPP-4 enzyme. This 
enzyme circulates in a soluble form in plasma, and is 
expressed in a wide variety of tissues including the kidney, 
liver, lung, and lymphocytes (Drucker and Nauck 2006). 
Importantly, this enzyme is responsible for the rapid degra-
dation and inactivation of the incretin hormones GLP-1 and 
GIP. DPP-4 inhibition increases levels of and extends the 
half-life of these circulating incretins, thereby prolonging 
their actions (Ahren 2007). GLP-1 levels after DPP-4 inhibi-
tion are increased, resulting in stimulation of insulin secretion 
and suppression of glucagon secretion in a fashion which is 
glucose-dependent (ie, glucose-appropriate). DPP-4 medi-
ated inhibition of glucagon secretion contributes to improved 
glucose homeostasis through suppression of hepatic glucose 
output. Inhibition of the enzyme has been shown to increase 
HOMA-B (homeostatic model assessment of beta cell func-
tion) and decrease the proinsulin/insulin ratio, suggestive 
of an increased insulin secretion which is accompanied by 
improvements in insulin production and processing (Raz 
et al 2006). Interestingly, rodent studies suggest that DPP-
4 inhibition may preserve beta cell mass; however, there 
are no data at present to support a similar effect in humans 
(Mu et al 2006). GIP levels are also increased via DPP-4 
inhibition – the clinical signiﬁ  cance of this is unclear, though, 
as individuals with type 2 diabetes appear to have decreased 
responsiveness to this incretin (Ahren 2007). The likelihood 
of hypoglycemia due to sitagliptin monotherapy is low, as the 
activity of the medication depends on hormones that exert 
their effects in a glucose-dependent manner.
Metformin
The precise mechanisms through which metformin exerts its 
glucose lowering effects are not entirely understood. How-
ever, its primary mode of action appears to be that of increas-
ing hepatic insulin sensitivity, resulting in decreased hepatic 
glucose output through suppression of gluconeogenesis and 
glycogenolysis (Goodarzi and Bryer-Ash 2005). Metformin 
may also modestly augment glucose uptake in peripheral tis-
sues, increase fatty acid oxygenation, and increase glucose 
metabolism in the splanchnic bed (Bailey 2005). Metformin’s 
effects appear to be at least in part mediated by adenosine 
monophosphate-activated protein kinase (AMPK), but it 
is unclear if this pathway represents the drug’s speciﬁ  c or 
unique target (Reitman and Schadt 2007). Administration 
of metformin to obese subjects was also found to increase 
levels of active GLP-1 after a glucose load: this phenomenon 
appears to occur through mechanisms other than DPP-4 
inhibition, and may instead be due to direct stimulation of 
GLP-1 secretion or a reduction in DPP-4 secretion (Mannucci 
et al 2001; Lenhard et al 2004). Importantly, the likelihood 
of hypoglycemia induced by metformin monotherapy is quite 
low, as the drug does not exert its effects through an increase 
in insulin secretion.
Pharmacology/pharmacokinetics
Sitagliptin
Sitagliptin is an orally bioavailable and active inhibitor of the 
DPP-4 enzyme, which may be administered with or without 
food. The drug is highly selective for DPP-4, with markedly 
greater afﬁ  nity for that enzyme than for the related enzymes 
DPP-8 and DPP-9 (Herman et al 2005). Sitagliptin rapidly 
inhibits the activity of DPP-4 in a dose-dependent fashion, 
with doses of 50 mg and 100 mg inhibiting the enzyme 
by 80% over 12 and 24 hours, respectively. Inhibition of 
DPP-4 activity by 80% results in a 2- to 3-fold increase in 
active GLP-1 levels, and is the level of inhibition at which 
near maximal glucose lowering is seen. Of the administered 
dose, 79% is excreted unchanged in the urine, via active 
tubular secretion (Herman et al 2005, 2007). The potential 
for adverse interactions with other medications is low, as 
the drug is minimally metabolized and does not appear to 
inhibit or induce cytochrome P450 enzymes. In particular, no 
alterations in the pharmacokinetics of other oral hypoglyce-
mic agents (including rosiglitazone, glyburide, and metfor-
min) have occurred after sitagliptin administration (Ahren 
2007; Herman et al 2007). The usual recommended dose of 
sitagliptin is 100 mg daily; however, as renal insufﬁ  ciency 
has been found to increase drug exposure, the dose should 
be reduced in individuals with modest or severe degrees of 
renal dysfunction. It is recommended that the daily dose be 
reduced to 50 mg daily if the creatinine clearance is less 
than 50 mL/min, and reduced further to 25 mg daily if the 
creatinine clearance is less than 30 mL/min. Patients who Vascular Health and Risk Management 2008:4(4) 747
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are prescribed sitagliptin therapy should have renal function 
assessed prior to and periodically during therapy, in order to 
ensure appropriate dosing (Merck and Co, Inc. 2007).
Metformin
Metformin is an orally administered medication which is 
50%–60% bioavailable. Administration with food may 
decrease its absorption, the clinical signiﬁ  cance of which 
is unknown. The drug is minimally protein-bound, and has 
few known drug interactions other than that known to occur 
with cimetidine, which increases metformin levels in plasma 
by up to 40%. The drug has an elimination half-life (t1/2) of 
approximately 6 hours. It is generally dosed 2–3 times daily, 
but is available in an extended release preparation which 
may be administered once a day. Eighty-ﬁ  ve percent of the 
maximal glucose-lowering effect is seen at a daily dose of 
500 mg 3 times daily, with a total daily dose of 2000 mg 
exerting the most effective glucose lowering (Scheen 1996; 
Bailey 2005).
Metformin is not metabolized prior to its complete 
excretion in the urine via glomerular ﬁ  ltration and tubular 
secretion. Decreases in renal function will decrease clearance 
of the medication.
Metformin accumulation has been associated with lactic 
acidosis: although this is a rare complication of therapy, the 
condition is fatal 50% of the time. The true likelihood of lactic 
acidosis occurring as a result of metformin accumulation is 
unclear. Although the incidence is reported to be 0.03 cases 
per 1000 patient-years of use, a recent systematic review of 
data from 206 trials of metformin therapy (47,846 patient-
years of use between 1959–2005) found no cases of fatal 
or nonfatal lactic acidosis to have occurred in conjunction 
with the drug (Salpeter et al 2006). However, given these 
concerns, the drug is contraindicated in the setting of renal 
dysfunction (males with a creatinine over 1.5 mg/dL, and 
females with a creatinine above 1.4 mg/dL), or in those at risk 
for lactic acidosis due to hypoperfusion of the kidney or other 
tissues. This includes individuals with a history of congestive 
heart failure requiring medical treatment, signiﬁ  cant hepatic 
dysfunction, or metabolic acidosis. The drug should also be 
discontinued pre-operatively, or in the setting of sepsis or an 
acute myocardial infarction. The drug must be discontinued 
prior to the administration of radiocontrast dye, and should be 
restarted only if renal function remains within an acceptable 
range at 48 hours after the procedure. Renal function must be 
assessed prior to and periodically during metformin therapy, 
particularly in the elderly in whom it is recommended that 
creatinine clearance be assessed in order to most accurately 
detect any signiﬁ  cant degree of renal dysfunction (Scheen 
1996; Bailey 2005).
Medication efﬁ  cacy and durability
Metformin
As a large number of studies have included the use of metfor-
min for glucose lowering, a complete review of this literature 
is beyond the scope of this article. In general, though, it is 
expected that metformin monotherapy for type 2 diabetes 
will result in HbA1c lowering of approximately 1.5%–2% 
(Goodarzi and Bryer-Ash 2005). Metformin monotherapy 
as studied in the UKPDS trial resulted in sustained glucose 
lowering for over 2 years on average; however, a secondary 
failure rate of 5%–10% per year was noted. This failure rate 
was comparable to that seen with sulfonylurea therapy, and 
likely reﬂ  ects a progressive loss of beta cell function which 
was not ameliorated with the use of metformin (UKPDS 
1998; Bailey 2005). Despite this deterioration in glycemic 
control over time, a reduction in major cardiovascular end-
points was seen in a group of obese UKPDS subjects treated 
preferentially with metformin (UKPDS 1998). As this was 
not clearly due to better glycemic control, it is theorized that 
this beneﬁ  t was due to unique favorable effects of metformin 
upon the cardiovascular system. For example, metformin 
therapy does not cause weight gain, and may in fact result in 
weight loss with an associated reduction in blood pressure. 
Although it is generally felt to be lipid neutral, metformin 
administration has been found to reduce levels of triglycer-
ides, total cholesterol, and LDL cholesterol in some clinical 
trials. Furthermore, metformin therapy may result in desir-
able physiologic changes including vasodilatation, increased 
ﬁ  brinolysis, and decreased platelet aggregation (Goodarzi 
and Bryer-Ash 2005). Metformin therapy has been proven 
useful in diabetes prevention, as its use in the Diabetes Pre-
vention Program trial reduced the annual incidence of type 2 
diabetes from 11% to 7.8% per year in patients with impaired 
glucose tolerance (Knowler et al 2002). It has recently been 
recommended that metformin therapy be initiated at the time 
of diagnosis of type 2 diabetes, in conjunction with lifestyle 
modiﬁ  cation (Nathan et al 2008).
Sitagliptin
Seven large phase III trials of sitagliptin as monotherapy 
or as part of a combination of drugs to treat type 2 diabetes 
have been published. Two similar studies of sitagliptin 
monotherapy enrolled 741 and 521 patients into 24-week 
and 18-week treatment periods. These study populations had 
mean baseline HbA1c levels of 8.0% and 8.1% respectively. Vascular Health and Risk Management 2008:4(4) 748
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In both trials, patients were randomized to treatment with 
sitagliptin 100 mg daily, sitagliptin 200 mg daily, or 
placebo. In the 18-week trial, sitagliptin 100 mg therapy 
reduced HbA1c by 0.6% compared with placebo, while the 
same dose reduced HbA1c by 0.8% in the 24-week study. 
No signiﬁ  cant difference in efﬁ  cacy was seen between the 
100 mg and 200 mg dosing groups in either trial; thus only 
the 100 mg dose has been used in subsequent studies. Low 
rates of hypoglycemia, stable body weight, and improvement 
in markers of beta cell function were seen with sitagliptin 
therapy in both monotherapy studies (Achsner et al 2006; 
Raz et al 2006).
Analysis of the efﬁ  cacy of sitagliptin therapy in addi-
tion to the thiazolidinedione pioglitazone was performed 
in a group of 353 individuals with a mean baseline HbA1c 
of 8.0%. These individuals, on pre-existing therapy of pio-
glitazone 30 or 45 mg per day, were randomized to receive 
add-on therapy with sitagliptin 100 mg daily or placebo 
for a 24-week treatment period. The addition of sitagliptin 
resulted in a mean reduction in HbA1c of 0.7% compared 
with placebo. Furthermore, signiﬁ  cant reductions in mean 
fasting blood glucose levels and improvements in markers 
of beta cell function were seen with active therapy compared 
with placebo. Sitagliptin therapy did not signiﬁ  cantly change 
in mean body weight compared with either baseline weight 
or the placebo group (Rosenstock et al 2006).
One 52-week noninferiority trial has been performed 
which compared the efﬁ  cacy of sitagliptin versus glipizide 
as add-on therapy to metformin. This trial of 353 individuals 
with a mean baseline HbA1c of 7.5% randomized patients 
to either sitagliptin 100 mg daily or glipizide 5 mg daily 
(uptitrated to a maximum of 20 mg daily), in addition to 
ongoing metformin treatment at a total daily dose of at least 
1500 mg. At 52 weeks, it was found that treatment with 
either sitagliptin or glipizide (at an average daily dose of 
10 mg) resulted in a signiﬁ  cant mean reduction in HbA1c 
of 0.7%, thus establishing noninferiority. Of note, sitagliptin 
therapy was associated with less hypoglycemia and a more 
favorable effect on weight than was glipizide. In particular, 
the sitagliptin group lost an average of 1.5 kg, while the 
glipizide group sustained a mean weight gain of 1.1 kg 
(Nauck et al 2007).
Sitagliptin and metformin combination 
therapy
Charbonnel et al performed a 24-week study of sitagliptin and 
metformin combination therapy in 701 subjects with a mean 
HbA1c of 8.0%. In this trial, participants were randomized in 
a 2:1 ratio to sitagliptin 100 mg daily or placebo, as adjunctive 
therapy to ongoing metformin treatment of at least 1500 mg 
daily. Sitagliptin therapy signiﬁ  cantly reduced HbA1c by 
0.7% compared with placebo, an effect that was sustained 
throughout the treatment period. Active therapy also resulted 
in a signiﬁ  cantly greater percentage of individuals achieving 
an HbA1c goal of less than 7% compared with placebo (47% 
vs 18%); provided signiﬁ  cant reductions in mean fasting 
and 2-hour glucose levels; and increased markers of beta 
cell function. Speciﬁ  cally, improvements in fasting insulin, 
c-peptide, proinsulin/insulin ratio, and HOMA-B were noted 
to be signiﬁ  cant with sitagliptin therapy compared with 
placebo. Sitagliptin therapy did not increase risk of hypogly-
cemia or adverse gastrointestinal side effects compared with 
placebo, and no signiﬁ  cant difference in mean body weight 
was noted (Charbonnel et al 2006).
A large study by Goldstein et al (2007) analyzed the 
effects on glycemic control of various doses of metformin, 
sitagliptin, combinations of both drugs, or placebo over 
24 weeks in 1091 individuals with baseline HbA1c values 
of 7.5%–11% (mean 8.8%). Participants were randomized 
to one of six treatment regimes: sitagliptin 100 mg/metfor-
min 2000 mg daily; sitagliptin 100 mg/metformin 1000 mg 
daily; metformin 2000 mg; metformin 1000 mg (all dosed 
in twice daily, evenly divided doses); sitagliptin 100 mg 
daily; or placebo. All active therapies as outlined above 
resulted in mean HbA1c reductions of 2.07%, 1.57%, 
1.30%, 0.99%, and 0.83% respectively compared with 
placebo. Of note, an additional open-label analysis of indi-
viduals with baseline HbA1c values greater than 11% dem-
onstrated that treatment with sitagliptin 100 mg/metformin 
2000 mg daily produced a within-group HbA1c reduction 
of 2.9%. In all treatment groups, the improvements in fast-
ing blood glucose and HbA1c values remained relatively 
stable after reaching a nadir at 6 weeks. Administration of 
combined sitagliptin and metformin increased HOMA-B 
more signiﬁ  cantly than did sitagliptin or metformin mono-
therapy. Rates of hypoglycemia with active therapy were 
low (ranging from 0.5% to 2.2%), and not signiﬁ  cantly 
different from placebo (0.6%). Reductions in mean body 
weight were small but signiﬁ  cant in all groups other than 
the sitagliptin monotherapy group, in which mean body 
weight remained stable at 24 weeks. Rates of adverse 
gastrointestinal side effects with combination therapy 
were similar to those reported with comparable dosing of 
metformin monotherapy (Goldstein et al 2007).
Finally, Hermansen et al performed a 24-week analysis 
of sitagliptin versus placebo therapy in patients inadequately Vascular Health and Risk Management 2008:4(4) 749
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controlled on glimepiride ± metformin therapy. These 441 
participants had a mean baseline HbA1c of 8.34%, and 
were randomized to sitagliptin 100 mg daily or placebo in 
addition to baseline therapy with glimepiride or glimepiride 
plus metformin. At 24 weeks, sitagliptin treatment had 
signiﬁ  cantly reduced HbA1c by 0.74% overall compared 
with placebo, with the most pronounced mean reduction 
in HbA1c (0.89%) seen in the group that had been treated 
with all three active drugs. In this trial, sitagliptin treatment 
resulted in a higher number of adverse events compared with 
placebo, due primarily to an increased rate of nonsevere 
hypoglycemia. Overall rates of hypoglycemia were 12.2% 
with sitagliptin, compared with 1.8% for placebo – most 
episodes could be explained by precipitating factors such as 
fasting or delayed meals. A mean increase in body weight 
of 0.8 kg was noted in the sitagliptin group, while the pla-
cebo group lost an average of 0.4 kg. Sitagliptin therapy 
appeared to be lipid neutral compared with placebo in this 
trial (Hermansen et al 2007).
Safety and tolerability
Sitagliptin therapy appears to be safe and well-tolerated by 
most, as outlined in the previous sections. When administered 
as monotherapy or in combination with agents other than 
sulfonylureas, sitagliptin therapy appears unlikely to cause 
hypoglycemia and is generally weight-neutral. However, 
when administered concomitantly with a sulfonylurea, rates 
of hypoglycemia and weight gain are signiﬁ  cantly greater 
than that seen with placebo. Other adverse effects noted to 
occur in clinical trials of DPP-4 inhibition have included 
increased reports of nasopharyngitis, upper respiratory 
infection, and headache – these were not likely to be severe 
or result in discontinuation of the medication. As previously 
noted, dosing of sitagliptin should be adjusted in persons 
with moderate or severe renal dysfunction; however, its use 
is not contraindicated in the setting of renal dysfunction. In 
the postmarketing period, reports of serious hypersensitivity 
reactions in conjunction with sitagliptin therapy have 
occurred – the causal relationship of the drug to these com-
plications is unclear at present. These reactions have included 
cases of anaphylaxis, angioedema, and exfoliative skin con-
ditions and thus the use of sitagliptin is contraindicated in 
individuals who have experienced a previous hypersensitivity 
reaction to the drug (Merck and Co, Inc. 2007).
Although sitagliptin may be used safely in the setting of 
renal dysfunction, the use of metformin in such a situation 
would be contraindicated. Thus it is imperative that the 
safety proﬁ  le of each drug be reviewed prior to prescription 
of a sitagliptin/metformin combination. Renal function 
must be assessed prior to and periodically during the use 
of both of these medications in order to ensure appropri-
ate dosing (sitagliptin) and safety of use (metformin). The 
most commonly reported adverse side effects associated 
with metformin therapy are gastrointestinal, and include 
abdominal pain, diarrhea, and anorexia – these side effects 
are estimated to occur in approximately 20% of metformin 
users (Goodarzi and Bryer-Ash 2005). Generally these 
side effects may be minimized by initiating a low dose of 
metformin, gradually uptitrating the metformin dose, and 
administering the medication with meals. Of note, the addi-
tion of sitagliptin to metformin therapy does not appear to 
cause a greater incidence of gastrointestinal side effects 
than does metformin alone. Other side effects associated 
with metformin therapy include reductions in vitamin B12 
levels, and reports of a metallic taste in the mouth (Goodarzi 
and Bryer-Ash 2005). Both sitagliptin and metformin are 
pregnancy category B. At present, inadequate information 
is available for either drug with which to make recom-
mendations for use in pregnancy, lactation, or pediatric 
populations.
Quality of life, satisfaction, 
and acceptability
Sitagliptin and metformin are medications that should be 
readily acceptable to most individuals with type 2 diabe-
tes. Both are oral agent medications, which are generally 
preferred to injection therapies and require no special sup-
plies for administration. Adherence and patient satisfaction 
may also increase with utilization of the newly available 
sitagliptin/metformin combination tablet. In addition to the 
increased convenience of a combination tablet, such medi-
cations often help to defray the costs of antihyperglycemic 
therapies. The gastrointestinal side effects associated with 
metformin therapy – although experienced by a signiﬁ  cant 
percentage of metformin users – can generally be minimized 
through slow upward titration in dosing and administration 
of the medication with meals, and do not seem more likely 
to occur when sitagliptin is used in conjunction with metfor-
min therapy. Additionally, these agents are unlikely to cause 
hypoglycemia when administered individually or in combina-
tion. Most attractive, perhaps, would be the effects of these 
two medications (or lack thereof) on body weight. Sitagliptin 
appears to be largely weight-neutral, and does not appear to 
interfere with any weight loss that might be conveyed by 
metformin therapy. The exception to this, however, appears 
to be when sitagliptin is added to sulfonylurea therapy: use Vascular Health and Risk Management 2008:4(4) 750
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of that particular combination has been associated with 
increases in hypoglycemia and weight gain.
Conclusions and place in therapy
Type 2 diabetes mellitus and the many complications thereof 
represent a major public health concern worldwide. Although 
the beneﬁ  ts of good glycemic control have been well docu-
mented, the majority of those affected by the disease have 
either not reached or maintained desirable levels of HbA1c. 
The reasons for this are multifactorial, and are at least partly 
explained by the inability of traditionally used drugs to arrest 
the progressive loss of beta cell function over time. Some of 
the factors contributing to poor glycemic control may perhaps 
be more easily remedied than others. Examples of potentially 
helpful strategies might include the use of medications that are 
dosed infrequently or in combination tablets to improve patient 
adherence; use of medications that are ﬁ  nancially accessible 
to patients; and medications with low rates of unpleasant side 
effects which might lead to drug discontinuation. Whether or 
not any of the newer classes of antihyperglycemic medications 
will prove useful in the maintenance of beta cell mass remains 
to be seen; however, some preliminary data suggest that this 
may be the case with DPP-4 inhibitors such as sitagliptin.
The combination of sitagliptin and metformin in type 2 
diabetes management has been shown in clinical trials to be 
effective in blood glucose lowering, with very low associated 
rates of hypoglycemia and no attenuation in the potential 
weight loss effects seen with metformin monotherapy. Use 
of this combination ﬁ  ts nicely with a recently published 
algorithm of recommended drug therapy for diabetes, as the 
strategy suggested by Nathan et al (2008) suggests initiation 
of metformin at the time of diagnosis and subsequent rapid 
intensiﬁ  cation of drug therapy should inadequate glycemic 
control persist. It is furthermore not unreasonable to assume 
that the use of sitagliptin/metformin combination therapy as 
a ﬁ  rst-line intervention would result in more effective blood 
glucose lowering than would metformin therapy alone. In 
addition, combination therapy implementing less than maxi-
mal doses of metformin might permit a signiﬁ  cant degree of 
glucose lowering with a minimum of metformin-associated 
gastrointestinal effects. Of note, though, the introduction 
of a sulfonylurea to this drug combination appears to be asso-
ciated with an increased likelihood of hypoglycemia as well 
as weight gain. Clearly, long-term studies will be needed to 
assess deﬁ  nitively the effectiveness of sitagliptin/metformin 
therapy in preserving beta cell mass and function over time, 
as well as any potential impact that this combination might 
have on the development of cardiovascular complications.
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